More on ROP
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $329.97 |
|
|||
| Open | $328.53 | ||||
| 52 Wk High | $195.93 | ||||
| 52 Wk Low | $155.79 | ||||
| Day High | $332.04 | ||||
| Day Low | $325.80 | ||||
| P/E | 61.50 | ||||
| EPS | $5.37 | ||||
| Volume | 3,559,770 | ||||
- FDA accepts Genentech's application for Lunsumio and Polivy combo
- FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma
- Chartwell Law Selects Aderant Expert Sierra to Drive Cloud Transformation, Supporting Firmwide Growth
- DAT: Spot truckload rates rise in May on capacity pressure across the market
- DAT’s Convoy Platform now shows reload options before carriers book
- FDA grants priority review for Genentech's Tecentriq in stage III colon cancer
- FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer
- Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
- Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
- Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection
Entities mentioned with ROP
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Dividend | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Twitter | View Related Stories »
- Third Point LLC | View Related Stories »
- Show More...
